Page 95 - The autoimmune hypothesis of narcolepsy and its unexplored clinical features M.S. Schinkelshoek

Conclusion
We confirm that treatment with SXB is associated with a decrease in BMI in NT1 patients, while modafinil treatment is not. For the majority of NT1 patients, BMI decrease therefore constitutes an additional beneficial effect of SXB. The weight loss is more pronounced in those with a higher BMI at baseline. Possible weight loss could therefore be another reason to opt for treatment with SXB in NT1, especially in those with a higher BMI. Due to the retrospective nature of this study further prospective and longitudinal studies are needed to confirm our results and further characterize BMI change dynamics.
Acknowledgements
The authors thank P.P. Buijserd-Amesz for her help in acquiring the data and J.W. Sander for critically reviewing this manuscript, specifically concerning the use of the English language.
Medication and BMI change
93
5